SLC5A2 and diabetes mellitus: In a recent cohort study other than those included in the meta-analysis, Eroglu et al. analyzed data for 152,591 patients with type 2 diabetes mellitus to examine whether the use of SGLT2 inhibitors is more closely associated than the use of other anti-diabetic agents with SCD (46).